New government drug repurposing programs: Opportunities and uncertainties.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38924430.
- Also identified by DOI 10.1126/scitranslmed.adl0998.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.
Medical subject headings
- Drug Repositioning